Technology ID
TAB-2636

Monoclonal Antibodies that Neutralize Norovirus

E-Numbers
E-226-2011-0
Lead Inventor
Chen, Zhaochun (NIAID)
Co-Inventors
Bok, Karin (NIAID)
Sosnovtsev, Stanislav (NIAID)
Green, Lisbeth Kim (NIAID)
Purcell, Robert (NIAID)
Applications
Vaccines­­­
Therapeutics
Therapeutic Areas
Infectious Disease
Immunology
Development Stages
Pre-Clinical (in vitro)
Development Status
  • Early-stage
  • In vivo data available (animal)
Research Products
Antibodies
ICs
NIAID
Vaccines and therapies to prevent and treat Norovirus infections do not exist, despite the worldwide prevalence of Norovirus infections. Outbreaks of human gastroenteritis attributable to Norovirus commonly occur in group setting, such as hospitals, nursing homes, schools, dormitories, cruise ships and military barracks.

This technology relates to chimpanzee-human chimeric monoclonal antibodies, which specifically bind to Norovirus and have therapeutic potential. The antibodies that were tested in a primate model of infection have shown protection against Norovirus. These Norovirus antibodies may have application as immunoprophylaxis to protect individuals from infections or as a possible treatment for infected individuals, or can be used to develop a diagnostic for detection of norovirus infections.
Commercial Applications
  • Therapeutics
  • Diagnostics
Competitive Advantages
  • There are currently no vaccines or therapeutics available against Norovirus infections
Licensing Contact:
Soukas, Peter
peter.soukas@nih.gov
Phone: 301-496-2644